Although GFLs seemed to provide clinical benefits in a subset of PD patients [13–17], none of the randomised placebo-controlled Phase II trials with either GDNF protein or adeno-associated virus vector-encoded neurturin (AAV2-NRTN) met their primary endpoints [16–21]. Here, NRTN is linked to Parkinson disease.